Skip to main content

$17.88 -0.10 (-0.56%)

High

$18.20

Low

$17.50

Trades

1,245

Turnover

$1,190,837

Volume

66,664
30 June 2023 at 4:10pm
Register to track CUV and receive email alerts.
Subject
CUV Ann: Notification regarding unquoted securities - CUV

CUV Ann: Two Grounds of Appeal Upheld by NICE Panel

CUV Ann: Notification of cessation of securities - CUV

CUV Ann: Presentation - Melbourne Twilight Briefing

CUV Ann: Change of Director's Interest Notice

CUV Ann: CLINUVEL Newsletter III - June 2023

CUV Ann: Strategic Update VI

CUV Ann: PRENUMBRA administered to moderate & severe stroke patients

CUV Ann: Expansion of global porphyria programs

CUV Ann: CLINUVEL Newsletter II - April 2023

CUV Ann: Investor Presentation - NYC Nasdaq Event

CUV Ann: Technical Note - CUV803 Study and AIS

CUV Ann: First stroke patient treated with PRENUMBRA Instant

CUV Ann: DNA Repair data presented at AAD Meeting

CUV Ann: Statement on Silicon Valley Bank

CUV Ann: Proposed issue of securities - CUV

CUV Ann: Commercial Update SCENESSE

CUV Ann: Relief from Quarterly Reporting

CUV Ann: CLINUVEL launches first dermatocosmetic product

CUV Ann: Proposed issue of securities - CUV

CUV Ann: Global SCENESSE demand drives increased revenues, earnings

CUV Ann: CUV Appendix 4D Half Year Report

CUV Ann: PRENUMBRA formulation completed for clinical trial use

CUV Ann: Chair's Letter

CUV Ann: Technical note - CUV151 results

CUV Ann: Afamelanotide reduces UV skin damage in a healthy population

CUV Ann: Quarterly Activities/Appendix 4C Cash Flow Report

CUV Ann: NEURACTHEL manufacturing processes advance

CUV Ann: Technical Note - Xeroderma Pigmentosum

CUV Ann: afamelanotide Reduces DNA Photodamage in XP

CUV Ann: CLINUVEL Newsletter I - January 2023

CUV Ann: CLINUVEL Newsletter VI - December 2022

CUV Ann: Notification of cessation of securities - CUV

CUV Ann: Presentation - Jefferies London Healthcare Conference

CUV Ann: CLINUVEL Newsletter V - November 2022

CUV Ann: Change of Director's Interest Notice

CUV Ann: Quarterly Activities/Appendix 4C Cash Flow Report Re-issued

CUV Ann: Quarterly Activities/Appendix 4C Cash Flow Report

CUV Ann: Results of Meeting

CUV Ann: Chair Address

CUV Ann: Melbourne Investor Briefing Presentation

CUV Ann: First vitiligo patient enrolled in monotherapy study

CUV Ann: Investor Presentation - Sydney

CUV Ann: Notice of Annual General Meeting/Proxy Form

CUV Ann: Strategic Update V

CUV Ann: Presentation - HC Wainright Global Investment Conference

CUV Ann: Annual General Meeting Date

CUV Ann: CLINUVEL submits label expansion for adolescent EPP patients

CUV Ann: S&P DJI Announces September 2022 Quarterly Rebalance

CUV Ann: CLINUVEL Investor Webinar Financial Results 2022

Register to track CUV and receive email alerts.

Similar Companies

CSL ...
CSL
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX